Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Anxiety
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Anxiety
    TopAbstracts in Anxiety 06/25/2008 - (DGNews)
    Pregabalin Effective for Fibromyalgia Pain Regardless of Patient Anxiety or Depression: Presented at EULAR - (DGDispatch)
    TopAbstracts in Anxiety 06/11/2008 - (DGNews)
    TopAbstracts in Anxiety 05/28/2008 - (DGNews)
    TopAbstracts in Anxiety 05/14/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Anxiety
    • Understanding and Managing the Fibromyalgia Syndrome
    • Accurate Diagnosis of Fibromyalgia Is Essential for Effective Management
    • Functional Neuroimaging Studies Illuminate Mechanisms Underlying Development of Fibromyalgia
    • Pharmacologic and Behavioral Approaches Expand Treatment Options for Fibromyalgia
    • Prevalence and Associated Factors for Suicidal Ideation and Behaviors in Obsessive-Compulsive Disorder

      Webcasts/CME archive

       Recent cases - Anxiety
        Recurrence of Suicidal Ideation Due to Treatment with Antidepressants in Anxiety Disorder: A Case Report
        Persistent Tardive Rebound Panic Disorder, Rebound Anxiety and Insomnia Following Paroxetine Withdrawal: a Review of Rebound-Withdrawal Phenomena
        Olfactory Reference Syndrome: Diagnostic Criteria and Differential Diagnosis
        Comedication with Sertraline and Phenprocoumon in Two Patients with Anxiety Disorders
        Self-Hypnosis for Anxiety Associated with Severe Asthma: A Case Report

        Cases archive
          




        my personal edition > anxiety > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Venlafaxine, Paroxetine, Both Work on Panic: Presented at APA

        By Roberta Friedman, PhD

        SAN FRANCISCO, CA -- May 22, 2003 -- Panic attacks can be eased by treating patients with either the selective serotonin reuptake inhibitor (SSRI) paroxetine or the newer agent venlafaxine, which acts on both serotonin and noradrenaline.

        Findings on the efficacy of paroxetine and venlafaxine in panic disorder were reported here on May 19th at the 156th Annual Meeting of the American Psychiatric Association.

        Karen Tourian, MD, with Wyeth, said the 2 agents "for the most part, were equal" in their ability to treat panic in the study of 634 patients with Diagnostic and Statistical Manual Revision IV diagnosis of panic disorder with or without agoraphobia. Some patients had resisted prior treatment for their condition.

        The study investigators, from Massachusetts General, Boston, Massachusetts, United States, tested doses of 75 and 150 mg a day of an extended-release formulation of venlafaxine and 40 mg a day of paroxetine to allow for European registration of the agent in this indication, Dr. Tourian explained.

        About 100 women and 50 men in their 30s comprised each arm of the trial.

        Dr. Tourian said venlafaxine onset of action appeared to be slightly faster, but the difference was not statistically significant.

        More than half of patients given active drug treatment were panic-free by the end of the trial. By comparison, a third of placebo-treated patients were panic-free at the study end (P<0.001). More than 75% of all active drug recipients could be classified as responders, Dr. Tourian said.

        Placebo comparisons showed that all drug treatments gave significantly lowered frequencies of panic attacks over the 12 weeks of treatment. Scores on the Panic Disorder Severity Scale also declined with each drug regimen compared with placebo.

        This study will be part of several to show efficacy of their agent in panic disorder, Dr. Tourian said. Wyeth, which funded the study, has not yet submitted these data to the United States Food and Drug Administration, she added.

        Panic can be treated with benzodiazepines, but these sedate and have addiction liability, she explained. Monoamine oxidase inhibitors also work for panic disorder but have problematic interactions with many foods. SSRIs "work pretty well" in panic, she said, "but are not as quick" as the other existing therapies.

        Wyeth funded the work.


        [Study title: Venlafaxine Extended Release and Paroxetine in the Short-Term Treatment of Panic Disorder. Abstract 204]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send